|Bid||7.92 x 800|
|Ask||7.95 x 900|
|Day's Range||7.09 - 8.02|
|52 Week Range||1.58 - 19.10|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 13, 2020 - Aug 15, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.00|
TORONTO, ON / ACCESSWIRE / July 30, 2020 / Edesa Biotech, Inc.
TORONTO, ON / ACCESSWIRE / June 15, 2020 / Edesa Biotech, Inc. (EDSA), a clinical-stage biopharmaceutical company, has received expedited approval from Health Canada to begin a Phase 2/3 clinical study of its investigational drug, EB05, which the company is developing as a potential treatment for moderate to severe COVID-19 patients. The company reported that it has EB05 drug product available now and is seeking government grants to accelerate the initiation and rollout of the study, beginning at up to 30 sites. Based on previous clinical data and the mechanism of action, the company believes that modulating this well understood signaling pathway could reduce the number of ICU patients and intubation/ventilation procedures, ultimately saving lives.
By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Update on Phase 2b Trial of EB01 Edesa Biotech, Inc. (NASDAQ:EDSA) is currently conducting a Phase 2b clinical trial of EB01 2.0% cream in patients with ACD. The randomized, double blind, placebo controlled, sample size adaptive design trial is expected to enroll approximately 46 patients in Part A randomized 1:1